A number of factors affect treatment adherence, including the therapeutic alliance, perceived perceived lack of control, risk of dependence on medications, stigma associated with medication use, and more.
It’s been tornados, volcanoes, epidemics, and more. Now we have COVID-19; is the coronavirus here to stay?
On Thursday, March 26, the FDA granted authorization for SomrystTM, a prescription-only digital therapeutic for treatment of chronic insomnia in patients aged 22 years or older.
A new study shows that meditative practice is surprisingly effective for bipolar depression. The late poet helps explain why.
This article describes common misconceptions about treatment of psychiatric illness during pregnancy and advocates for a logical and thoughtful approach to designing a treatment plan.
The FDA accepts a New Drug Application for novel antidepressant.
Over the past two decades, deaths associated with alcohol abuse have increased, but little data point to demographic changes.
New research discovered mid-pregnancy insomnia may be a marker for both concurrent and postpartum anxiety.
An accurate assessment of bipolar disorder requires psychiatric evaluation of a range of symptoms marked by extreme mood changes and other factors described in brief.
An overview of the theoretical and empirical literature linking PTSD, substance use, and IPV, as well as risk factors for depression and other psychiatric disorders.